Author pages are created from data sourced from our academic publisher partnerships and public sources.
Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer
- K. Bakirhan, J. Sharma, R. Pérez-Soler, Haiying Cheng
- Current Treatment Options in Oncology
- 4 March 2016
Opinion statementLung cancer is the leading cause of cancer-related deaths worldwide. In the USA, ≈60 % of lung cancer cases are diagnosed in elderly patients (≥65 years of age). However, elderly… Expand
Update of systemic immunotherapy for advanced urothelial carcinoma.
PURPOSE Until recently, therapeutic options for metastatic urothelial carcinoma (UC) were limited to cytotoxic chemotherapy. Cisplatin-based combination chemotherapy has proven benefit in the… Expand
The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy
Prior to the last decade, treatment for lung cancer was differentiated only by the main histological groups of small cell lung cancer (SCLC) and NSCLC. However, it is now known that differences in… Expand
Emerging treatment for ALK-positive lung cancer
ABSTRACT Introduction: Lung cancer is associated with poor prognosis and limited benefit from chemotherapy. The treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the… Expand
Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era.
e17506Background: Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for both lung metastases and secondary primary cancers of the lung. Given the histopathologic similarity… Expand
New & Emerging Drugs for Squamous Cell Lung Cancer
Lung Cancer is the leading cause of cancer-related death worldwide. Squamous cell lung cancer (SQCLC) is the second most common histology (20-30% of cases) among non-small cell lung cancers (NSCLC),… Expand
Multiple Endocrine and Neoplastic Diseases After Unsuccessful Treatment of Hepatitis C With Interferon and Ribavirin.
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.
BACKGROUND Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regarding… Expand
Unusual pattern of KRAS mutations in inner city patients with NSCLC.
e20033Background: KRAS mutations (mut) occur in 15-25% of non-squamous NSCLC and may be associated with poor survival and primary EGFR TKI resistance. Distinct subgroups of KRAS-mut non-squamous… Expand
Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies
- Diego A. Adrianzen Herrera, Shlomit A. Goldberg-Stein, A. Sankin, Judy Sarungbam, J. Sharma, B. Gartrell
- Front. Oncol.
- 30 April 2018
The radiographic appearance of bone metastases is usually determined by tumor histology and can be osteolytic, osteoblastic, or mixed. We present a patient with coexistent bone metastasis from… Expand